Calithera Biosciences Inc., of South San Francisco, reported results from a phase I trial testing CB-839, an inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple-negative breast cancer (TNBC) at the 2017 San Antonio Breast Cancer Symposium in San Antonio Of the 37 evaluable patients treated with at least 600 mg of CB-839 twice a day, there were eight partial responses (22 percent), and disease control, defined as response or stable disease, was seen in 22 patients (59 percent). Read More
Horizon Discovery Group plc, of Cambridge, U.K., and ERS Genomics Ltd., of Dublin, extended their 2014 nonexclusive, worldwide license agreement to significantly expand Horizon's license coverage for the use of the CRISPR gene-editing technology. Read More
Tyme Technologies Inc., of New York, which is developing cancer therapeutics, said it has raised gross proceeds of approximately $5 million from its at-the-market financing facility. Read More
HONG KONG – Pfizer Inc. will bring Basilea Pharmaceutica Ltd.'s novel antifungal medicine to China and other major Asian markets as it works to meet a significant unmet need, one that is a leading cause of death across Asia. Read More
By combining the concept of synthetic lethality with drug delivery via nanoparticles, researchers have extended survival in xenograft mouse models of p53-driven endometrial tumors. Read More
LONDON – The U.K. is not due to leave the EU until the end of March 2019 but time has already run out for the pharma industry, which is being forced to activate plans based on the worst-case scenario that there will be no agreement on regulatory alignment or any transition period. Read More
Australia's CSL Ltd. said it expects to spend between $450 million and $550 million on its largest-ever study, a phase III trial of CSL-112, an I.V. infusion formulation of human apolipoprotein A-I intended to reduce early recurrent cardiovascular events in heart attack survivors. Separately, the company paid $15 million up front to spark a collaboration and purchase option agreement with Canada's Vitaeris Inc. Together, the companies will work to expedite the development of clazakizumab, an anti-IL-6 monoclonal antibody, as a therapy for solid organ transplant rejection. Read More
RT-002 achieved "a trifecta of positive clinical results," Revance Therapeutics Inc. CEO Dan Browne said, pointing to across-the-board success in a pair of phase III trials with next-generation neuromodulator DaxibotulinumtoxinA for injection (RT-002), which turned up positive top-line results in alleviating moderate to severe glabellar (frown) lines in the clinical program called Sakura. Read More
